Seikagaku Corporation

Seikagaku Kogyo Kabushiki Kaisha

Nobuo Sugiura

Koji Kimata

Toshio Ninomiya

Sakaru Suzuki

Katsukiyo Sakurai

Yoshimitsu Kakuta

Takuo Osawa

Satoshi Shimokata

Shigehisa Aoki

Shinichi Iwasaki

Koji Room 1201 Esupoa-Yashiroguchi Kimata

A chondroitin polymerase having such properties that it transfers GlcUA and GalNAc alternately to a non-reduced terminal of a sugar chain from a GlcUA donor and a GalNAc donor, respectively, and the like; and a process for producing the chondroitin polymerase.

Chondroitin polymerase and DNA encoding the same

Provided are a method for producing a fraction containing more than 50% of CH represented by the general formula (1), which comprises at least the step of allowing a glucuronic acid donor, an N-acetylgalactosamine donor, a saccharide receptor, a chondroitin polymerase derived from theK4 strain, and Mnat a final concentration of 0.02 to 100 mM to coexist, and performing a reaction thereof under conditions of 20 to 40&#xb0; C. and pH 6 to 8 for 0.5 minutes to 4 hours, and a method for producing a fraction containing more than 50% of CH represented by the general formula (2), which comprises at least the step of performing the reaction under same conditions for 10 hours or longer, which enable industrial scale production of a CH fraction of a controlled even number saccharide and odd number saccharide content ratio by a simple procedure at a low cost.(GlcA-GalNAc)&#x2003;&#x2003;(1)GalNAc-(GlcA-GalNAc)&#x2003;&#x2003;(2)(In the formula, GlcA represents a glucuronic acid residue, GalNCAc represents a N-acetylgalactosamine residue, - represents a glycosidic bond, and n represents an arbitrary integer.)

Process for preparation of chondroitin fraction

A method for producing a chondroitin sugar chain comprises reacting a glucuronic acid donor, an N-acetyl galactosamine donor, a sugar receptor and a bacterial cell enzyme which synthesizes chondroitin in the presence of a surfactant. The surfactant is selected from polyoxyethylene octadecyl amine, n-decanoyl-N-methylglucamide, sodium cholate, n-octyl-&#x3b2;-D-thioglucopyranoside, n-nonyl-&#x3b2;-D-thiomaltopyranoside, sucrose monocholate, sucrose monocaprate, and sucrose monolaurate. The chondroitin sugar chain has all the following properties: a weight average molecular weight: 50,000 or more when measured by gel filtration chromatography; it is completely degraded to disaccharides with chondroitinase ABC; and when the sugar chain is decomposed with chondroitinase ABC and the decomposed products are subjected to a disaccharide analysis, substantially all of them correspond to an unsaturated disaccharide unit of chondroitin.

Long-chain chondroitin sugar chain and method for producing the same and method for promoting synthesis of chondroitin

Disclosed are: (A) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, or (B) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 including deletion, substitution or addition of one or several amino acid residues and having chondroitin synthase activity; a nucleic acid encoding the polypeptide; a method for producing the polypeptide, comprising at least the steps of: (1) expressing the nucleic acid to produce the polypeptide; and (2) collecting the polypeptide produced in the step (1); and a crystal of the polypeptide. The crystal may be a monoclinic or tetragonal crystal.

Modified chondroitin synthase polypeptide and crystal thereof

This invention relates to compounds prepared by linking glycosaminoglycan to phospholipid or lipid, which are expected to exert a pharmacological effect for inhibiting metastasis because of their excellent function to inhibit adhesion of cancer cells to blood vessel endothelial cells and extracellular matrix. This phospholipid- or lipid-linked glycosaminoglycan can be produced for example by: cleaving and oxidizing reducing terminal group of glycosaminoglycan, and allowing an aldehyde group or a lactone compound of the thus-formed derivative or a carboxyl group in the glycosaminoglycan chain to react with a primary amino group of a phospholipid; or linking a glycosaminoglycan derivative to a phospholipid or a lipid by allowing a primary amino group of the derivative to react with a carboxyl group of the phospholipid or lipid. This phospholipid- or lipid-linked glycosaminoglycan is useful as a metastasis inhibitor because it has no toxicity.

Metastasis inhibitor composition comprising a phospholipid-linked

This invention provides an antirheumatic composition which comprises a lipid-bound glycosaminoglycan or a salt thereof as an active ingredient and a pharmaceutically acceptable carrier and has an effect to inhibit extension of pannus.

Growing community of inventors

Gifu, Japan

Nobuo Sugiura